Mylan Updates Litigation Status on PaclitaxelPITTSBURGH--(BUSINESS WIRE)--Dec. 23, 2003--Mylan Laboratories Inc. (NYSE:MYL) today reported that the U.S. District Court for the Western District of Pennsylvania has entered judgment in favor of Napro BioTherapeutics, Inc. and Faulding Pharmaceutical Co. in the patent infringement suit regarding Mylan's paclitaxel product.

Mylan Vice Chairman and CEO, Robert J. Coury stated, "Mylan historically has had a very small share of the paclitaxel market and as such its contribution to our sales has been de minimis. That being said, we disagree with the court's rulings and intend to file an appeal with the Federal Circuit." A May 2004 trial date has been set to rule on damages in the case.

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Bertek Pharmaceuticals Inc., that develop, manufacture and market an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com.

This press release includes statements that constitute "forward-looking statements," including with regard to the district court's rulings and the Company's intention to appeal the decision. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: a subsequent business decision not to appeal the ruling; a decision by the appellate court to uphold the district court's ruling; subjectivity inherent in any assumptions and estimates with respect to a product's impact on sales; and the other risks detailed in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

    CONTACT: Mylan Laboratories Inc.
             Kris King, 724-514-1800

    SOURCE: Mylan Laboratories Inc.